CivicaScript,® a nonprofit company dedicated to bringing low-cost generic medicines to U.S. consumers, announced today that it has lowered the price of its lead product, Abiraterone Acetate Tablets, ...

Eberle, R.Ph., M.B.A. "We've secured volume discounts for our abiraterone product that we are passing along to our members and to patients. This price reduction is proof that our model is working." ...

Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer is associated with better clinical outcomes. Triplet therapy that includes darolutamide vs ...

Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

Future Oncol. 2010;6(5):665-679.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...

Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most commonly diagnosed cancer and the second leading cause of cancer-related death for U.S. men. This ...